Trials / Completed
CompletedNCT04915820
Iron and COVID-19 Vaccine Response
Iron and Vaccine-preventable Viral Disease
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 121 (actual)
- Sponsor
- Jomo Kenyatta University of Agriculture and Technology · Academic / Other
- Sex
- Female
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
Vaccines often underperform in Africa compared to high-income countries. Why vaccines do not work as well in Africa remains uncertain. Malnutrition likely plays a role. Our study objective is to assess whether iron deficiency anaemia in young women impairs their immune response to the COVID-19 vaccine, and whether iron treatment improves their response.
Detailed description
Group 1 (immediate iron treatment) will receive iron treatment before vaccination. Women in both groups will receive the 1st dose of the COVID-19 vaccine. Vaccine response will be measured 28 and 56 days after the first vaccine administration in both groups. At 28 days, participants will receive the 2nd dose of the COVID-19 vaccine. Group 2 (delayed iron treatment) will receive iron treatment at study end.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Ferinject | intravenous iron carboxymaltose |
Timeline
- Start date
- 2021-05-29
- Primary completion
- 2021-09-09
- Completion
- 2021-09-09
- First posted
- 2021-06-07
- Last updated
- 2025-09-04
Locations
1 site across 1 country: Kenya
Source: ClinicalTrials.gov record NCT04915820. Inclusion in this directory is not an endorsement.